Bispecific Antibodies: A New Frontier in Haematologic Malignancies
EMJ Hematology · 23.07.2026 · 60
DOI: 10.33590/emjoncol/e3d3rf08 ↗Kurz gefasst
Fachartikel in der Zeitschrift EMJ Hematology, online erschienen am 23.07.2026. Verfasst von EMJ. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
How are Bispecific Antibodies Shaping Haematologic Cancer Care? 2017 It was approved for patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic a leukemia.3 Blinatumomab works by binding CD19, a surface antigen expressed on normal and malignant B cells, and CD3 on T cells, redirecting T-cell cytotoxicity towards CD19-positive malignant B cells in patients with B-cell acute lymphoblasti c leukaemia (B-ALL).2017 In 2017, blinatumomab was the first bispecific antibody to receive FDA approval for a haematological malignancy.Future Directions Next-generation bispecific antibodies are being engineered with extended half-lives and reduced cytokine release profiles to improve safety and dosing convenience.5
Zitieren
APA
EMJ (2026). Bispecific Antibodies: A New Frontier in Haematologic Malignancies. EMJ Hematology, 60. https://doi.org/10.33590/emjoncol/e3d3rf08
Vancouver
EMJ. Bispecific Antibodies: A New Frontier in Haematologic Malignancies. EMJ Hematology. 2026:60. doi:10.33590/emjoncol/e3d3rf08
BibTeX
@article{EMJ2026,
author = {EMJ},
title = {Bispecific Antibodies: A New Frontier in Haematologic Malignancies},
journal = {EMJ Hematology},
year = {2026},
pages = {60},
doi = {10.33590/emjoncol/e3d3rf08}
}
EUVIMED